

# Suzanne Oparil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5986888/publications.pdf>

Version: 2024-02-01

257  
papers

52,809  
citations

23544

58  
h-index

1282

225  
g-index

267  
all docs

267  
docs citations

267  
times ranked

37451  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. American Journal of Kidney Diseases, 2022, 79, 677-687.e1.	2.1	2
2	Factors Associated With Not Having a Healthcare Visit in the Past Year Among US Adults With Hypertension: Data From NHANES 2013-2018. American Journal of Hypertension, 2022, 35, 132-141.	1.0	7
3	Nocturnal blood pressure dipping in treated hypertensives: insights from the SPRINT trial. European Journal of Preventive Cardiology, 2022, 29, e25-e28.	0.8	1
4	Using web-based training to improve accuracy of blood pressure measurement among health care professionals: A randomized trial. Journal of Clinical Hypertension, 2022, 24, 255-262.	1.0	7
5	Treatment for Mild Chronic Hypertension during Pregnancy. New England Journal of Medicine, 2022, 386, 1781-1792.	13.9	215
6	Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. Hypertension, 2022, 79, 775-784.	1.3	4
7	An Update on Refractory Hypertension. Current Hypertension Reports, 2022, 24, 225-234.	1.5	16
8	Depressive Symptoms and Incident Hospitalization for Heart Failure: Findings From the REGARDS Study. Journal of the American Heart Association, 2022, 11, e022818.	1.6	4
9	What is the association of renin-angiotensin-aldosterone system inhibitors with COVID-19 outcomes: retrospective study of racially diverse patients?. BMJ Open, 2022, 12, e053961.	0.8	1
10	Pet Ownership and the Risk of Arterial Hypertension and Cardiovascular Disease. Current Hypertension Reports, 2022, 24, 295-302.	1.5	4
11	Medication-Na <sup>+</sup> -ve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. American Journal of Hypertension, 2022, 35, 731-739.	1.0	3
12	Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure. Journal of the American Heart Association, 2022, 11, e025406.	1.6	4
13	Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. Kidney360, 2022, 3, 1253-1262.	0.9	5
14	Migrating Populations and Health: Risk Factors for Cardiovascular Disease and Metabolic Syndrome. Current Hypertension Reports, 2022, 24, 325-340.	1.5	17
15	Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	0.7	0
16	What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question. International Journal of Environmental Research and Public Health, 2022, 19, 8206.	1.2	3
17	Cardiovascular Disease Risk Reduction and Body Mass Index. Current Hypertension Reports, 2022, 24, 535-546.	1.5	6
18	Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension. JACC: Heart Failure, 2021, 9, 100-111.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. Hypertension, 2021, 77, 435-444.	1.3	8
20	Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <math>130/80</math> mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?. Blood Pressure, 2021, 30, 79-81.	0.7	0
21	Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT. Journal of General Internal Medicine, 2021, 36, 2221-2229.	1.3	2
22	Response to "Comment" on the Story of the Silent Killer, a History of Hypertension: Its Discovery, Diagnosis, Treatment, and Debate. Current Hypertension Reports, 2021, 23, 7.	1.5	0
23	Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes " from single pill combinations to monitoring of a nationwide health insurance database. Blood Pressure, 2021, 30, 1-2.	0.7	0
24	Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes. Hypertension, 2021, 77, 1391-1398.	1.3	2
25	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2021, 384, 1921-1930.	13.9	214
26	Maintaining Normal Blood Pressure Across the Life Course. Hypertension, 2021, 77, 1490-1499.	1.3	6
27	Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. Circulation, 2021, 143, 2244-2253.	1.6	75
28	Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. Hypertension, 2021, 77, 1804-1814.	1.3	5
29	Coffee and Arterial Hypertension. Current Hypertension Reports, 2021, 23, 38.	1.5	23
30	Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood) Tj ETQq0 0 0 rgBT /Overlçck 10 Tf 5	2.1	8
31	Cuff-less measurements of blood pressure: are we ready for a change?. Blood Pressure, 2021, 30, 205-207.	0.7	7
32	Treatment of early hypertension among persons living with HIV in Haiti: Protocol for a randomized controlled trial. PLoS ONE, 2021, 16, e0254740.	1.1	2
33	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. Hypertension, 2021, 78, 555-558.	1.3	28
34	Racial Differences in Blood Pressure Control Following Stroke: The REGARDS Study. Stroke, 2021, 52, 3944-3952.	1.0	9
35	Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection. Blood Pressure, 2021, 30, 267-268.	0.7	0
36	Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. Journal of the American Heart Association, 2021, 10, e019434.	1.6	14

#	ARTICLE	IF	CITATIONS
37	Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. <i>Blood Pressure</i> , 2021, 30, 1-3.	0.7	16
38	Reasons for Uncontrolled Blood Pressure Among US Adults: Data From the US National Health and Nutrition Examination Survey. <i>Hypertension</i> , 2021, 78, 1567-1576.	1.3	6
39	The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. <i>Blood Pressure</i> , 2021, 30, 327-331.	0.7	4
40	Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022479.	1.6	10
41	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008322.	1.6	9
42	SPRINT Revisited: Updated Results and Implications. <i>Hypertension</i> , 2021, 78, 1701-1710.	1.3	9
43	Chronic hypertension in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 532-541.	0.7	76
44	The AJMS Celebrates # 200!. <i>American Journal of the Medical Sciences</i> , 2020, 359, 61-62.	0.4	0
45	The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension. <i>Blood Pressure</i> , 2020, 29, 1-2.	0.7	0
46	Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 496-504.	1.3	59
47	The role of exercise in the reversal of IGF-1 deficiencies in microvascular rarefaction and hypertension. <i>GeroScience</i> , 2020, 42, 141-158.	2.1	28
48	Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. <i>Hypertension</i> , 2020, 75, 510-515.	1.3	23
49	Forty-Year Shifting Distribution of Systolic Blood Pressure With Population Hypertension Treatment and Control. <i>Circulation</i> , 2020, 142, 1524-1531.	1.6	6
50	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , 2020, 41, 3363-3373.	1.0	103
51	Case of Episodic and Positional Hypertension. <i>Hypertension</i> , 2020, 76, 614-621.	1.3	1
52	Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. <i>JAMA Internal Medicine</i> , 2020, 180, 1655.	2.6	52
53	Preeclampsia—Pathophysiology and Clinical Presentations. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1690-1702.	1.2	305
54	The Story of the Silent Killer. <i>Current Hypertension Reports</i> , 2020, 22, 72.	1.5	31

#	ARTICLE	IF	CITATIONS
55	Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines. <i>Current Hypertension Reports</i> , 2020, 22, 66.	1.5	67
56	The International Society of Hypertension Guidelines 2020 "a new drug treatment recommendation in the wrong direction?". <i>Blood Pressure</i> , 2020, 29, 264-266.	0.7	2
57	Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?. <i>Blood Pressure</i> , 2020, 29, 341-343.	0.7	2
58	Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction. <i>ESC Heart Failure</i> , 2020, 7, 1700-1710.	1.4	24
59	Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2059-2066.	1.3	9
60	Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. <i>American Journal of Hypertension</i> , 2020, 33, 741-747.	1.0	14
61	Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2122-2132.	3.0	25
62	Obesity, Hypertension, and Bariatric Surgery. <i>Current Hypertension Reports</i> , 2020, 22, 46.	1.5	16
63	Weight Reduction for Obesity-Induced Heart Failure with Preserved Ejection Fraction. <i>Current Hypertension Reports</i> , 2020, 22, 47.	1.5	14
64	Global Blood Pressure Screening. <i>Hypertension</i> , 2020, 76, 318-320.	1.3	1
65	Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?. <i>Blood Pressure</i> , 2020, 29, 199-201.	0.7	0
66	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. <i>Journal of Hypertension</i> , 2020, 38, 1396-1406.	0.3	23
67	Aortic blood pressure and arterial stiffness in patients with controlled resistant and non-resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2020, 22, 167-173.	1.0	2
68	How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers. <i>Blood Pressure</i> , 2020, 29, 68-69.	0.7	0
69	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. <i>Hypertension</i> , 2020, 75, 660-667.	1.3	57
70	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. <i>Blood Pressure</i> , 2020, 29, 135-136.	0.7	31
71	Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. <i>JAMA Network Open</i> , 2020, 3, e2025127.	2.8	9
72	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. <i>Journal of Hypertension</i> , 2020, Publish Ahead of Print, .	0.3	2

#	ARTICLE	IF	CITATIONS
73	Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. <i>Journal of Hypertension</i> , 2020, 38, 2144-2145.	0.3	14
74	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 524.	3.8	285
75	Sex Differences in Hypertension and Stroke Risk in the REGARDS Study. <i>Hypertension</i> , 2019, 74, 749-755.	1.3	47
76	Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. <i>Hypertension</i> , 2019, 74, 652-659.	1.3	15
77	Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury. <i>Journal of Applied Physiology</i> , 2019, 127, 444-456.	1.2	7
78	Lower Blood Pressure Thresholds Raise the Bar in Pregnancy. <i>Circulation Research</i> , 2019, 125, 195-197.	2.0	6
79	Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. <i>Hypertension</i> , 2019, 74, 276-284.	1.3	26
80	Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes. <i>Blood Pressure</i> , 2019, 28, 356-357.	0.7	5
81	What is the first choice for blood pressure treatment?. <i>Lancet, The</i> , 2019, 394, 1782-1784.	6.3	4
82	The PARAGON-Heart failure trial “another disappointment for heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 276-278.	0.7	0
83	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 553.	3.8	786
84	Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. <i>Free Radical Biology and Medicine</i> , 2019, 134, 343-349.	1.3	14
85	New data on antihypertensive drugs and risk of cancer: should we worry?. <i>Blood Pressure</i> , 2019, 28, 1-3.	0.7	9
86	Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. <i>Blood Pressure</i> , 2019, 28, 144-145.	0.7	0
87	The PARAGON Heart Failure trial “ongoing investigation of the angiotensin receptor antagonist/nephrilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 215-216.	0.7	3
88	Treatment of Resistant and Refractory Hypertension. <i>Circulation Research</i> , 2019, 124, 1061-1070.	2.0	117
89	Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. <i>Journal of Clinical Hypertension</i> , 2019, 21, 451-459.	1.0	18
90	Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 49, 346-355.	1.4	18

#	ARTICLE	IF	CITATIONS
91	Epicardial Adipose Tissue and Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2019, 21, 36.	1.5	47
92	Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?. <i>Blood Pressure</i> , 2019, 28, 75-76.	0.7	5
93	Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction. <i>JACC: Heart Failure</i> , 2019, 7, 1032-1041.	1.9	7
94	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. <i>Journal of Hypertension</i> , 2019, 37, 2216-2224.	0.3	7
95	State of the Art: the Not-So-Great Wall of America. <i>Current Hypertension Reports</i> , 2019, 21, 97.	1.5	0
96	Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2019, 73, 132-141.	1.3	29
97	O-Linked $\beta$ -N-Acetylglucosamine Modification of A20 Enhances the Inhibition of NF- $\kappa$ B (Nuclear Factor- $\kappa$ B) Activation and Elicits Vascular Protection After Acute Endoluminal Arterial Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1309-1320.	1.1	31
98	New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. <i>Blood Pressure</i> , 2018, 27, 62-65.	0.7	16
99	Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial. <i>Journal of Hypertension</i> , 2018, 36, 904-915.	0.3	30
100	Impact of the SPRINT Trial on Hypertension Management. <i>Annual Review of Medicine</i> , 2018, 69, 81-95.	5.0	6
101	Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). <i>Hypertension</i> , 2018, 71, 1064-1074.	1.3	11
102	Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). <i>Hypertension</i> , 2018, 71, 848-857.	1.3	190
103	Hypertension. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18014.	18.1	636
104	Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions. <i>Blood Pressure</i> , 2018, 27, 1-2.	0.7	6
105	Accuracy of Blood Pressure Measurement Devices in Pregnancy. <i>Hypertension</i> , 2018, 71, 326-335.	1.3	74
106	What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?. <i>Journal of Hypertension</i> , 2018, 36, 37-40.	0.3	3
107	VEGF nanoparticles repair the heart after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H278-H284.	1.5	101
108	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1816-1824.	2.2	14

#	ARTICLE	IF	CITATIONS
109	2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 313-313.	0.7	14
110	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. <i>Journal of the American Heart Association</i> , 2018, 7, e009326.	1.6	79
111	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	1.1	14
112	Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1338.	3.8	116
113	Obesity and Pulmonary Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 99.	1.5	34
114	Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients. <i>Circulation Research</i> , 2018, 123, 531-534.	2.0	4
115	Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. <i>Blood Pressure</i> , 2018, 27, 247-248.	0.7	47
116	Effect of sleeve gastrectomy on hypertension. <i>Journal of the American Society of Hypertension</i> , 2018, 12, e19-e25.	2.3	13
117	Take a Blood Pressure Pill or Benefit from Renal Denervation?. <i>European Heart Journal</i> , 2018, 39, 3010-3012.	1.0	2
118	Reply. <i>Journal of Hypertension</i> , 2018, 36, 1423-1424.	0.3	1
119	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018, 391, 2335-2345.	6.3	526
120	Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. <i>Blood Pressure</i> , 2018, 27, 185-187.	0.7	5
121	Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk. <i>Current Hypertension Reports</i> , 2018, 20, 77.	1.5	34
122	Final Farewell to Alberto Zanchetti MD. <i>European Heart Journal</i> , 2018, 39, 2616-2617.	1.0	0
123	Revisiting ASCOT 16 years later. <i>Lancet, The</i> , 2018, 392, 1092-1094.	6.3	1
124	Novel Medical Treatments for Hypertension and Related Comorbidities. <i>Current Hypertension Reports</i> , 2018, 20, 90.	1.5	12
125	Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. <i>Hypertension</i> , 2018, 72, 343-349.	1.3	29
126	Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1998-2008.	3.3	16



#	ARTICLE	IF	CITATIONS
127	Assessment of vascular function in low socioeconomic status preschool children: a pilot study. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 101-109.	2.3	6
128	The INTERSALT Study and the complex relationship between salt intake and blood pressure. <i>Blood Pressure</i> , 2017, 26, 65-66.	0.7	2
129	The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. <i>European Heart Journal</i> , 2017, 38, ehw549.	1.0	65
130	The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke. <i>Blood Pressure</i> , 2017, 26, 131-132.	0.7	9
131	Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury Response. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1168-1177.	1.6	7
132	Hypertension and Its Complications in a Young Man With Autoimmune Disease. <i>Hypertension</i> , 2017, 69, 536-544.	1.3	1
133	Hypertension in Women. <i>Hypertension</i> , 2017, 70, 19-26.	1.3	63
134	Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women. <i>Current Hypertension Reports</i> , 2017, 19, 41.	1.5	6
135	Incident Cardiovascular Disease Among Adults With Blood Pressure $\geq 140/90$ mmHg. <i>Circulation</i> , 2017, 136, 798-812.	1.6	60
136	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2812-2823.	3.0	364
137	Race and sex differences in ambulatory blood pressure measures among HIV+ adults. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 420-427.e3.	2.3	11
138	Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 357-367.	2.1	60
139	Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	88
140	Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 827-835.	1.3	12
141	The Global Burden of Disease Study 2015 and Blood Pressure. <i>Blood Pressure</i> , 2017, 26, 1-1.	0.7	14
142	Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering) Treatment Strategies. <i>Stroke</i> , 2017, 48, 190-196.	1.0	3
143	Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?. <i>Blood Pressure</i> , 2017, 26, 319-320.	0.7	2
144	Masked Hypertension. <i>Current Hypertension Reports</i> , 2017, 19, 81.	1.5	4

#	ARTICLE	IF	CITATIONS
145	Risk stratification of sudden cardiac death in hypertension. <i>Journal of Electrocardiology</i> , 2017, 50, 798-801.	0.4	20
146	Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. <i>New England Journal of Medicine</i> , 2017, 377, 733-744.	13.9	160
147	Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2017, 377, 745-755.	13.9	157
148	The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection. <i>Scientific Reports</i> , 2017, 7, 7563.	1.6	10
149	Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials. <i>Blood Pressure</i> , 2017, 26, 257-258.	0.7	2
150	White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. <i>Hypertension</i> , 2017, 70, 645-651.	1.3	21
151	<sup>123</sup> I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 372-376.	1.4	1
152	Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults. <i>JAMA Internal Medicine</i> , 2017, 177, 67.	2.6	59
153	Ambulatory Blood Pressure Monitoring in Individuals with HIV: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0148920.	1.1	25
154	Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 930-938.e9.	2.3	15
155	HOPE-3 and SPRINT: two landmark trials with different outcomes?. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 477-481.	2.3	1
156	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2673.	3.8	991
157	Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 493-499.	2.3	50
158	The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease. <i>Blood Pressure</i> , 2016, 25, 276-279.	0.7	3
159	Refractory Hypertension. <i>Hypertension</i> , 2016, 67, 1085-1092.	1.3	59
160	Blood Pressure in 2016: increased impact factor and change of editors. <i>Blood Pressure</i> , 2016, 25, 331-332.	0.7	0
161	BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?. <i>Current Cardiology Reports</i> , 2016, 18, 98.	1.3	6
162	Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. <i>Hypertension</i> , 2016, 68, 995-1003.	1.3	42

#	ARTICLE	IF	CITATIONS
163	The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 238-244.	0.8	5
164	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 847-856.	2.3	56
165	Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <math>\leq 120/80\text{ mmHg}</math> Target?. <i>Circulation</i> , 2016, 134, 1308-1310.	1.6	24
166	The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure. <i>Hypertension</i> , 2016, 68, 39-45.	1.3	77
167	The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below <math>120\text{ mmHg}</math>. <i>Blood Pressure</i> , 2016, 25, 1-3.	0.7	35
168	SPS3 Evidence Supports Intensive Blood Pressure Control. <i>Circulation</i> , 2016, 133, 552-554.	1.6	8
169	SPRINT Trial Results. <i>Hypertension</i> , 2016, 67, 263-265.	1.3	79
170	Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H705-H715.	1.5	12
171	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. <i>Hypertension</i> , 2016, 67, 550-555.	1.3	17
172	Cardiovascular care for older adults: hypertension and stroke in the older adult. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 373-9.	0.2	6
173	Refractory Hypertension. <i>Hypertension</i> , 2015, 66, 126-133.	1.3	98
174	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 845-854.	2.3	15
175	New Approaches in the Treatment of Hypertension. <i>Circulation Research</i> , 2015, 116, 1074-1095.	2.0	233
176	Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. <i>American Journal of Medicine</i> , 2015, 128, 707-714.e2.	0.6	23
177	Is Blood Pressure Control for Stroke Prevention the Correct Goal?. <i>Stroke</i> , 2015, 46, 1595-1600.	1.0	62
178	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1314-1321.	1.2	103
179	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 769-779.	2.3	36
180	Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 670-679.	2.3	14

#	ARTICLE	IF	CITATIONS
181	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2015, 373, 2103-2116.	13.9	4,880
182	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. <i>European Heart Journal</i> , 2015, 36, 219-227.	1.0	458
183	Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007-2010. <i>PLoS ONE</i> , 2014, 9, e105888.	1.1	13
184	Update on Clinical Guidelines for Treatment of Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	0
185	Updated Guidelines for Management of High Blood Pressure in Japan. <i>Hypertension Research</i> , 2014, 37, 484-487.	1.5	6
186	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). <i>Clinical Trials</i> , 2014, 11, 532-546.	0.7	408
187	The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 891-897.	2.3	35
188	Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 898-908.	2.3	34
189	Targeted Delivery of Pulmonary Arterial Endothelial Cells Overexpressing Interleukin-8 Receptors Attenuates Monocrotaline-Induced Pulmonary Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1539-1547.	1.1	13
190	Guidelines for Managing High Blood Pressure-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 295.	3.8	5
191	Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 405-413.	2.3	113
192	Effect of Chlorthalidone, Amlodipine, and Lisinopril on Visit-to-Visit Variability of Blood Pressure: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , 2014, 16, 323-330.	1.0	55
193	Low Sodium Intake - Cardiovascular Health Benefit or Risk?. <i>New England Journal of Medicine</i> , 2014, 371, 677-679.	13.9	69
194	Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 808-819.	2.3	18
195	A Controlled Trial of Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 370, 1393-1401.	13.9	1,848
196	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 507.	3.8	6,625
197	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1071-1078.	1.2	164
198	Estrogen Effects on Vascular Inflammation Are Age Dependent. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1477-1485.	1.1	57

#	ARTICLE	IF	CITATIONS
199	Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Hypertension</i> , 2013, 61, 977-986.	1.3	36
200	Long-Term Follow-Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). <i>Journal of Clinical Hypertension</i> , 2013, 15, 542-554.	1.0	26
201	Novel strategies for treatment of resistant hypertension. <i>Kidney International Supplements</i> , 2013, 3, 357-363.	4.6	4
202	Increased Dietary Sodium Is Related to Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension and Hyperaldosteronism. <i>Chest</i> , 2013, 143, 978-983.	0.4	61
203	J Curve in Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 281-290.	0.8	7
204	Refractory Hypertension: Definition, Prevalence, and Patient Characteristics. <i>Journal of Clinical Hypertension</i> , 2012, 14, 7-12.	1.0	160
205	Mortality and Morbidity During and After the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , 2012, 14, 20-31.	1.0	38
206	The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population. <i>Hypertension</i> , 2011, 57, 160-166.	1.3	397
207	Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Circulation</i> , 2011, 124, 1811-1818.	1.6	49
208	Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. <i>Journal of Hypertension</i> , 2011, 29, 161-170.	0.3	10
209	Can Catheter-Based Renal Denervation Be Used Safely and Effectively to Substantially Reduce Blood Pressure in Treatment-Resistant Hypertensive Patients?. <i>Current Cardiology Reports</i> , 2011, 13, 478-480.	1.3	1
210	New challenges in blood pressure goals and assessment. <i>Nature Reviews Cardiology</i> , 2011, 8, 73-75.	6.1	11
211	Mechanisms of Glucosamine-Mediated Relaxing Responses in Isolated Rat Aortic Rings. <i>FASEB Journal</i> , 2011, 25, 1020.4.	0.2	0
212	A STITCH Saves Time and Lowers Blood Pressure. <i>Current Hypertension Reports</i> , 2010, 12, 146-148.	1.5	0
213	Severity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension. <i>Journal of Clinical Sleep Medicine</i> , 2010, 06, 363-368.	1.4	123
214	Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism. <i>Hypertension</i> , 2010, 55, 1137-1142.	1.3	137
215	Angiotensin Receptor Blocker and Dihydropyridine Calcium Channel Blocker Combinations: An Emerging Strategy in Hypertension Therapy. <i>Postgraduate Medicine</i> , 2009, 121, 25-39.	0.9	51
216	Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. <i>Hypertension</i> , 2009, 54, 475-481.	1.3	474

#	ARTICLE	IF	CITATIONS
217	Subgroup Analyses of an Efficacy and Safety Study of Concomitant Administration of Amlodipine Besylate and Olmesartan Medoxomil: Evaluation by Baseline Hypertension Stage and Prior Antihypertensive Medication Use. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 54, 427-436.	0.8	29
218	Results of an Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 911-921.	1.0	25
219	Characterization of Resistant Hypertension&lt;subitle&gt;Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion&lt;/subitle&gt;. <i>Archives of Internal Medicine</i> , 2008, 168, 1159.	4.3	254
220	Does improving hypertension control involve more than just pills?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 182-183.	3.3	1
221	Renin Inhibitors in the Management of Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 706-707.	1.0	1
222	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. <i>Lancet</i> , The, 2007, 370, 221-229.	6.3	432
223	Women and Hypertension. <i>Cardiology in Review</i> , 2006, 14, 267-275.	0.6	44
224	Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. <i>New England Journal of Medicine</i> , 2006, 354, 1685-1697.	13.9	854
225	Gender and Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2005, 7, 300-309.	1.0	63
226	Ethnicity and Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2005, 7, 357-364.	1.0	12
227	Fibroblast growth factor upregulates periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. <i>American Journal of Hypertension</i> , 2004, 17, S172.	1.0	1
228	Estrogen attenuates inflammatory mediator mRNA expression in balloon injured rat carotid arteries. <i>American Journal of Hypertension</i> , 2004, 17, S242.	1.0	0
229	Estrogenic vasoprotection is lost in aged rats. <i>American Journal of Hypertension</i> , 2004, 17, S244-S245.	1.0	0
230	Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1148-1155.	1.2	214
231	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2560.	3.8	18,097
232	Pathogenesis of Hypertension. <i>Annals of Internal Medicine</i> , 2003, 139, 761.	2.0	501
233	Sex hormones and hypertension. <i>Cardiovascular Research</i> , 2002, 53, 688-708.	1.8	453
234	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet</i> , The, 2002, 359, 995-1003.	6.3	4,917

#	ARTICLE	IF	CITATIONS
235	Are there meaningful differences in blood pressure control with current antihypertensive agents?. American Journal of Hypertension, 2002, 15, S14-S21.	1.0	11
236	Cardiovascular effects of estrogen. American Journal of Hypertension, 2001, 14, S186-S193.	1.0	38
237	Genetic Variation in Angiotensin-Converting Enzyme Does Not Prevent Development of Cardiac Hypertrophy or Upregulation of Angiotensin II in Response to Aortocaval Fistula. Circulation, 2001, 103, 1012-1016.	1.6	31
238	Hormone Replacement Therapy and Stroke: Are the Results Surprising?. Circulation, 2001, 103, 620-622.	1.6	12
239	Direct In Vivo Evidence Demonstrating Neointimal Migration of Adventitial Fibroblasts After Balloon Injury of Rat Carotid Arteries. Circulation, 2000, 101, 1362-1365.	1.6	256
240	Essential Hypertension. Circulation, 2000, 101, 329-335.	1.6	829
241	Hypertension in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1862-1866.	1.8	127
242	Estrogen Inhibits Vascular Smooth Muscle Cell-Dependent Adventitial Fibroblast Migration In Vitro. Circulation, 1999, 100, 1639-1645.	1.6	55
243	Bradykinin in the Heart. Circulation, 1999, 100, 2305-2307.	1.6	34
244	Case study. American Journal of Hypertension, 1998, 11, 192S-194S.	1.0	0
245	Sexually Dimorphic Response of the Balloon-Injured Rat Carotid Artery to Hormone Treatment. Circulation, 1997, 95, 1301-1307.	1.6	70
246	Blood Pressures and Cardiovascular Homeostasis in Mice Having Reduced or Absent Angiotensin-Converting Enzyme Gene Function. Hypertension, 1997, 30, 128-133.	1.3	43
247	Cardiac renin angiotensin system in hypertrophy and the progression to heart failure. Heart Failure Reviews, 1996, 1, 63-72.	1.7	3
248	Medroxyprogesterone Attenuates Estrogen-Mediated Inhibition of Neointima Formation After Balloon Injury of the Rat Carotid Artery. Circulation, 1996, 94, 2221-2227.	1.6	94
249	The Calcium Antagonists in the 1990s. American Journal of Hypertension, 1991, 4, 396S-405S.	1.0	26
250	Dietary NaCl Loading Enhances Antihypertensive Effect of Guanabenz in Spontaneously Hypertensive Rats. American Journal of Hypertension, 1989, 2, 435-439.	1.0	3
251	Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure. Lung, 1988, 166, 209-219.	1.4	4
252	Hypoxia-Induced Oxygen Tolerance: Maintenance of Endothelial Metabolic Function. Experimental Lung Research, 1988, 14, 887-896.	0.5	5

#	ARTICLE	IF	CITATIONS
253	Hyperoxia-induced Converting Enzyme Insufficiency in Conscious Rat: Cardiovascular Effects. <i>Experimental Lung Research</i> , 1987, 12, 37-56.	0.5	8
254	Enalapril in low-renin essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 297-302.	2.3	26
255	Lofexidine and clonidine in moderate essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 752-757.	2.3	14
256	Role of the Renal Sympathetic Nerves in the Development and Maintenance of Hypertension in the Spontaneously Hypertensive Rat. <i>Journal of Clinical Investigation</i> , 1980, 66, 971-978.	3.9	197
257	Hypertension in Women. , 0, .		35